HERON THERAPEUTICS, INC. /DE/ 8-K

What Happened

• On January 9, 2026, Heron Therapeutics, Inc. (HRTX) filed a Form 8-K under Item 7.01 (Regulation FD Disclosure) to announce preliminary financial results for the three months ended December 31, 2025 and for the full year 2025.
• The company issued a press release dated January 9, 2026 announcing those preliminary quarterly and annual results; the press release is furnished as Exhibit 99.1 to the 8-K.

Key Details

• Filing date: January 9, 2026 (Form 8-K, Item 7.01 — Regulation FD Disclosure).
• Reporting period: three months ended December 31, 2025 and full year 2025 (preliminary results).
• Press release: furnished as Exhibit 99.1 to the 8-K.
• Interactive XBRL cover page included as Exhibit 104 (Inline XBRL).

Why It Matters

• Preliminary financial results give investors an early look at Heron’s recent earnings and revenue trends ahead of final audited statements or an annual report; these disclosures can influence short-term market expectations.
• Because the press release was furnished under Regulation FD, the information was publicly disclosed to ensure fair access for all investors. Retail investors should read the Exhibit 99.1 press release for the specific figures announced and monitor subsequent filings (e.g., Form 10-K or later 8-Ks) for final audited results and additional details.